Katherine High, Spark's president and chief scientific officer, expressed her enthusiasm for the early
clinical data related to SPK - 8011: «The encouraging start of our SPK - 8011
clinical trial reinforces the strength of our gene therapy platform, delivers
human proof - of -
concept in a second liver - mediated disease — a significant achievement
in the gene therapy field — and positions us well to potentially transform the current treatment approach for this life - altering disease with a one - time intervention.»
Once we have demonstrated the proof of
concept in animal studies, the next goal will be to work towards the first
human clinical trial with graphene devices during intraoperative mapping of the brain.
Now that proof of
concept has been demonstrated, Hooper said, the next step is to secure funding and approval for Phase I
clinical trials in humans to assess the safety profile of the antibodies.